VRXA Veraxa Biotech AG - Post de-SPAC: institutional ownership and insider trading
8 funds reported holding $600K of Veraxa Biotech AG - Post de-SPAC in their latest 13F filings; in Q2 2026 funds net bought $910K, with 8 new positions and 0 funds selling out; over the last 12 months insiders bought $115K and sold $0 on the open market.
Largest institutional holders of VRXA
- UBS Group AG (UBS) — $296K
- GEODE CAPITAL MANAGEMENT, LLC — $225K
- HRT FINANCIAL LP — $35.0K
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $20.4K
- PICTON MAHONEY ASSET MANAGEMENT — $19.3K
- WOLVERINE ASSET MANAGEMENT LLC — $3.29K
- JPMORGAN CHASE & CO (JPM, AMJB, VYLD, JPM-PC, JPM-PD, JPM-PJ, JPM-PK, JPM-PL, JPM-PM) — $859
- Caitong International Asset Management Co., Ltd — $11
Recent VRXA insider trades
- Oct 20, 2026: Ziegler Christoph Samuel bought 30,000 shares ($32.7K)
- Aug 27, 2026: Baumann Oliver Rolf bought 50,000 shares ($75.0K)
- Aug 27, 2026: Antz Christoph Rudiger bought 5,000 shares ($7.65K)
5%+ owners
- Deck David Lukas: 18.0% (Schedule 13D, filed Jun 16, 2026)
- Xlife Sciences AG: 16.3% (Schedule 13D, filed Jun 15, 2026)
- European Molecular Biology Laboratory: 16.2% (Schedule 13D, filed Jun 16, 2026)
- Schoeni Gilbert Edgar: 15.9% (Schedule 13D, filed Jun 15, 2026)